Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
Key Points
- Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels.
- The company now has the full clinical trial data required to start filing for approvals of the drug for chronic weight management with global regulators.
- The rate of side effects and treatment discontinuations in the study, called ATTAIN-2, appeared to be generally consistent with two recent phase three trials on the pill, called orforglipron.
